Although whether CAFs are associated with good or poor prognosis remains unclear and is contradictory in different studies [59], these results provide strengthened evidence for cross‐regulation of ITGA11 and COL11A1 in cancer stroma, suggesting that ITGA11+/ COL11A1+ CAFs may be a new candidate biomarker for clinical outcomes based on CAF‐mediated tumorigenicity in patients with NSCLC. This evidence concerns the gene COL11A1 and cancer.